Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comprehensive disease management for schizophrenia.

P F Buckley1

  • 1Case Western Reserve University and Northcoast Behavioral Healthcare System, Cleveland, Ohio 44106, USA.

Drugs of Today (Barcelona, Spain : 1998)
|July 16, 2003
PubMed
Summary

New antipsychotic medications for schizophrenia are more effective and better tolerated than older drugs. Research continues to explore their full benefits, including cognitive and anti-aggressive effects, and reducing substance abuse.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder.

Translational psychiatry·2017
Same author

Psychotherapy and schizophrenia.

The Journal of psychotherapy practice and research·2012
Same author

Latent structure of psychotic experiences in the general population.

Acta psychiatrica Scandinavica·2011
Same author

Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?

Acta psychiatrica Scandinavica·2007
Same author

Negative symptoms of schizophrenia: a problem that will not go away.

Acta psychiatrica Scandinavica·2007
Same author

Schizophrenia today: what do we know-and how sure are we?

Journal of psychiatric practice·2005

Area of Science:

  • Pharmacology
  • Psychiatry
  • Neuroscience

Background:

  • Schizophrenia treatment is rapidly evolving.
  • New generation antipsychotics offer improved efficacy and tolerability over conventional options.

Purpose of the Study:

  • To review the advancements in schizophrenia pharmacotherapy.
  • To highlight the broader efficacy profile of atypical antipsychotics.
  • To outline future research and clinical directions.

Main Methods:

  • Literature review of recent pharmacotherapy studies.
  • Analysis of efficacy and tolerability data for new generation antipsychotics.
  • Synthesis of current research trends and clinical recommendations.

Main Results:

Related Experiment Videos

  • Newer antipsychotics demonstrate superior efficacy and tolerability.
  • Atypical antipsychotics show potential for cognitive enhancement, antiaggressive effects, and reducing comorbid substance abuse.
  • Ongoing research aims to differentiate the specific benefits of each new drug.

Conclusions:

  • New generation antipsychotics represent a significant advancement in schizophrenia treatment.
  • Future efforts must ensure access to these treatments and implement comprehensive care models.
  • Further research is crucial for optimizing the use of these novel pharmacotherapies.